March 31 Genocea Biosciences Inc* Positive 12 month efficacy data from its phase 2 dose optimization trial evaluating gen-003 for treatment of genital herpes* Consistent efficacy across potential phase 3 clinical trial endpoints * Anticipate reporting virologic efficacy data for gen-003 from our recently-initiated phase 2b study in q3 of 2016 * Anticipate reporting clinical efficacy data at 6 months post dosing around end of 2016 for gen-003 from recently-initiated phase 2b study * Anticipate conducting end of phase 2 meeting with fda in q1 of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)Source: http://reuters.comRead more… Let’s take a look at three life science stocks going into orbit or have the potential to. Current herpes treatments only partly control clinical signs and symptoms and viral losing, a procedure which drives disease transmission. 29, 2016 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. Viral shedding is what causes the spread of genital herpes. In the third quarter of 2016, Genocea expects to report virologic efficacy data from a Phase 2b trial to confirm the efficacy of GEN-003 manufactured with Phase 3 processes at increased scale. Additional information was obtained through the U.S.
MediciNova, Inc. The Company is developing Resolaris, a potential first-in-class protein therapeutic, for the treatment of rare myopathies with an immune component (RMICs). For trading purposes, my entry point would have been $5.50 looking for a run to $7. My stop loss would have been $5.25, fearing anything below that and the stock would start to fill in the gap up.